Biosimilars targeting Humira launched in the U.S. in early 2023 ... intends to shift to a hybrid in-person and virtual sales model by June 30, lowering its customer-facing staff.

AbbVie's flagship product, Humira, has been a key revenue driver ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ABBV is one of these AI-selected gems?

Novartis is looking to take full advantage of its branded and generics/biosimilar business model, with Cosentyx and a Humira biosimilar will help it provide a broader offering. "When patients are ...

Offsetting Humira's expected declines ... (such as off-label marketing or litigation related to side effects) and model base case annual legal costs at 1.5% of non-GAAP net income (at the midrange ...

Skyrizi sales beat the Zacks Consensus Estimate of $3.58 billion and our model estimate of $3.56 billion. AbbVie’s flagship product Humira recorded a sales decline of 48.7% to $1.68 billion in ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.